Clinical Trials Logo

Pancreatic Cancer Stage IV clinical trials

View clinical trials related to Pancreatic Cancer Stage IV.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04953962 Completed - Clinical trials for Pancreatic Cancer Stage IV

Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer

Start date: December 18, 2021
Phase: Phase 2
Study type: Interventional

Multicenter, randomized, open-label, parallel group phase 2 study to assess the efficacy and tolerance of four combinations of CBP501, cisplatin, and nivolumab administered once every 21 days to patients with stage IV exocrine pancreatic cancer and WBC < 10,000/mm3 at screening.

NCT ID: NCT04181645 Completed - Clinical trials for Pancreatic Cancer Stage IV

SHR- 1210 Combined With Paclitaxel (Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Start date: June 29, 2019
Phase: N/A
Study type: Interventional

This is an open-label, single center, non-randomized, phase I trial to evaluate safety and efficacy of using the combination treatment of SHR-1210 with Paclitaxel-albumin and gemcitabine of metastatic PDAC.

NCT ID: NCT03412799 Completed - Clinical trials for Stage IV Pancreatic Cancer

Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Start date: June 4, 2018
Phase: Phase 1
Study type: Interventional

This is an open-label phase 1A/1B study to assess the safety, tolerability and pharmacokinetics of SBP-101 when combined with nab-paclitaxel and gemcitabine in subjects with previously untreated metastatic pancreatic ductal adenocarcinoma and to identify a recommended phase 2 dose. The study will also assess preliminary efficacy of the 3-drug treatment combination.